Company intelligence / Profile preview

Innovent Biologics

Ownership: Public · 1801.HK
Employees: ~350
Development stage: Commercial

Overview

Innovent Biologics has developed a robust portfolio of biologic drugs with several already marketed in China. Its lead oncology product sintilimab has shown strong clinical efficacy as an anti-PD1 antibody. The company also markets biosimilars such as bevacizumab, rituximab, adalimumab, among others. It continues to expand its pipeline into autoimmune disorders, metabolic disease, and ophthalmology with both novel biologics and small molecules. Clinical results have supported regulatory approvals for several programs in China; global expansion efforts are ongoing.[3][5]

Therapeutic areas: OphthalmologyOncologyImmunologyCardiovascular
Modalities: Monoclonal antibodies (mAbs)Small molecules (e.g., pemigatinib)Recombinant proteins
Industry: Biotech

Drug pipeline

59 assets

sintilimab

58 more assets in the full pipeline.

Partnerships

Collaborations with Eli Lilly & Co.Roche/Genentech for certain assets/products.[3][5]

Financials

Market cap: $19.2B
Total revenue: $2B
Enterprise value: $16.6B

Beyond the preview

Go deeper on Innovent Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innovent Biologics.